Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
2,998.8
2.9 (0.10%)

 

  • STI Straits Times Index
    2,998.8
    2.9 (0.10%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,601.5
    -0.3 (-0.02%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    29,962.5
    320.2 (1.08%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,583.1
    16.7 (0.47%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    28,523.3
    -110.2 (-0.38%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,429.8
    107.9 (1.71%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 3,229.5M
  • Value: 1,486.1M
  • Rise: 248
  • Fall: 131
  • Unch: 400

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Oceanus^0.049+0.008
MarcoPolo Marine0.023+0.006
Jiutian Chemical0.109-
P5 Capital0.038+0.008
Citicode0.001-
Blumont0.006+0.001
AusGroup0.038+0.001
ETC Singapore0.051+0.001
DISA0.003+0.001
Asian Micro0.019+0.002

World Indices

World Indices
Name Last Change
Nasdaq 13,197.2 +198.7
HSI 29,962.5 +320.2
HSCEI 11,949.4 +215.0
Jakarta 6,429.8 +107.9
Nikkei 225 28,523.3 -110.2
SSE Comp 3,583.1 +16.7
Shanghai A 3,755.8 +17.5
Shanghai B 250.4 +0.4
KOSPI 3,114.6 +21.9

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

180 LIFE SCIENCES CORP 180 LIFE SCIENCES CORP.
Updated on 19 Jan 2021 (End of trading day)
Last (USD): 3.090 Change: - High: 3.180 Remarks: -
Change (%): - Low: 2.840
Open 3.000 Yesterday's Close 3.09
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 1,062,106 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a - Trailing EPS (USD) e - NAV (USD) b -
PE a - Trailing PE f - Price / NAV b -
Dividend (USD) d - Cash In Hand (USD) g - Issued & Paid-up Shares c 18,032,000
Dividend Yield (%) d - Price / Cash In Hand g - Treasury Shares h -
Market Cap (M) 55.719 Enterprise Value (M) 55.719
Piotroski F Score - Exchange Code ATNF Par Value ( $ ) n.a.
52 Weeks Volatility (%) n.a. Free Float (%) 50.6
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 24 Nov 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 09 Nov 2020.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference 180 LIFE SCIENCES CORP NASDAQ 55.719 - - - -
Industry Pharmaceuticals: Major NASDAQ 2,760.473 - 63.017 3.9174 0.004
Local Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 138,014.124 102.955 54.872 11.3173 2.605
Local Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 127,181.149 39.089 10.354 1.7888 2.314
Local Peer ROYALTY PHARMA PLC NASDAQ 32,418.694 13.804 13.804 7.2821 -
Local Peer VIATRIS INC NASDAQ 20,928.000 1,245.714 78.559 1.6678 -
Local Peer CUREVAC NV NASDAQ 18,371.637 - - 20.5777 -
Local Peer REPLIGEN CORP NASDAQ 12,024.767 561.611 274.338 10.6899 -
Local Peer ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS NASDAQ 8,454.700 - - 7.5767 -
Local Peer ALLAKOS INC NASDAQ 6,670.019 - - 16.1186 -
Local Peer TURNING POINT THERAPEUTICS INC NASDAQ 6,518.689 - - 9.2913 -
Local Peer GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 NASDAQ 5,170.986 7.390 6.661 0.8247 4.012
Local Peer HUTCHISON CHINA MEDITECH SPON ADS EACH REPR 5 ORD SHS NASDAQ 4,839.338 - - 14.1453 -
Local Peer ATEA PHARMACEUTICALS INC NASDAQ 4,555.496 - - -59.5400 -
Other Local Peers LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), APELLIS PHARMACEUTICALS INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), OPKO HEALTH INC (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), GENERATION BIO CO (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), KRONOS BIO INC (NASDAQ), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), CULLINAN MANAGEMENT INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ANNEXON INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), GRITSTONE ONCOLOGY INC (NASDAQ), ATHENEX INC (NASDAQ), PETIQ INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), PROVENTION BIO INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), GOSSAMER BIO INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), GRAYBUG VISION INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), VERU INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), INOZYME PHARMA INC (NASDAQ), ESSA PHARMA INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), UROVANT SCIENCES LTD (NASDAQ), BEYONDSPRING INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), AC IMMUNE SA (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), DURECT CORP (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), 89BIO INC (NASDAQ), CLENE INC (NASDAQ), IMMUNIC INC (NASDAQ), TRICIDA INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), GALECTO INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), MUSTANG BIO INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), IMARA INC (NASDAQ), OBSEVA SA (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), HARROW HEALTH INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), EVOLUS INC (NASDAQ), NOVAN INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), POLYPID LTD (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), EYENOVIA INC (NASDAQ), GENPREX INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), PROPHASE LABS INC (NASDAQ), MEDIWOUND LTD (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), PETROS PHARMACEUTICALS INC (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), MANNATECH INC (NASDAQ), PAINREFORM LTD (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), MILLENDO THERAPEUTICS INC (NASDAQ), ENTERA BIO LTD (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), TELIGENT INC NEW (NASDAQ)
Global Peer JOHNSON & JOHNSON NYSE 428,524.861 28.343 25.228 6.6466 2.304
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 238,540.031 33.844 33.381 4.3781 1.906
Global Peer MERCK & CO INC NYSE 210,473.196 21.383 18.272 7.2115 2.726
Global Peer PFIZER INC NYSE 204,160.032 12.547 23.510 3.1285 3.958
Global Peer ABBVIE INC NYSE 198,050.425 25.255 27.060 12.9698 3.278
Global Peer ELI LILLY AND COMPANY NYSE 189,862.395 40.937 34.071 39.3341 1.301
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 150,815.715 43.855 - 3.0068 2.482
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 132,353.131 22.667 21.239 14.1028 1.557
Global Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 96,927.715 16.357 11.986 5.2482 5.048
Global Peer WUXI APPTEC HKEx 579,251.132 275.940 213.541 15.9592 0.103
Other Global Peers TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), HANSOH PHARMA (HKEx), INNOVENT BIO (HKEx), CANSINOBIO-B (HKEx), JUNSHI BIO (HKEx), REMEGEN-B (HKEx), SINOPHARM (HKEx), AKESO-B (HKEx), SH PHARMA (HKEx), HYGEIA HEALTH (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), BAIYUNSHAN PH (HKEx), CHINARES PHARMA (HKEx), EVEREST MED-B (HKEx), CMS (HKEx), HENLIUS-B (HKEx), SIMCERE PHARMA (HKEx), CHINAGRANDPHARM (HKEx), TRAD CHI MED (HKEx), ADC THERAPEUTICS SA (NYSE), ZYMEWORKS INC (NYSE), HEPALINK (HKEx), INNOCARE-B (HKEx), OCUMENSION-B (HKEx), Kimia Farma Tbk. (IDX), SSY GROUP (HKEx), ANTENGENE-B (HKEx), CSTONE PHARMA-B (HKEx), UNITED LAB (HKEx), AMNEAL PHARMACEUTICALS INC (NYSE), CKLIFE SCIENCES (HKEx), TONGRENTANGCM (HKEx), IMMUNOTECH-B (HKEx), HUA MEDICINE-B (HKEx), IGBB (Bursa), Soho Global Health Tbk. (IDX), SHINEWAY PHARM (HKEx), STARPHARMA HOLDINGS LIMITED (ASX), FUSEN PHARM (HKEx), AFT PHARMACEUTICALS LTD (ASX), BSTEAD (Bursa), PYC THERAPEUTICS LIMITED (ASX), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), TOT BIOPHARM-B (HKEx), PHARMA (Bursa), LANNETT CO INC (NYSE), DAWNRAYS PHARMA (HKEx), ZHONGZHIPHARM (HKEx), CRESO PHARMA LTD (ASX), RACE ONCOLOGY LTD (ASX), CH BIOTECH SER (HKEx), BIOMX INC (NYSE American), IX Biopharma (SGX), RECCE PHARMACEUTICALS LTD (ASX), NC HEALTHCARE (HKEx), IP (SET), Merck Tbk. (IDX), Phapros Tbk. (IDX), NOXOPHARM LTD (ASX), KOTRA (Bursa), MODERN CHI MED (HKEx), Hyphens Pharma (SGX), ONCOSIL MEDICAL LIMITED (ASX), NOVA (Bursa), BIOHLDG (Bursa), AGEX THERAPEUTICS INC (NYSE American), EXOPHARM LTD (ASX), ANNOVIS BIO INC (NYSE American), PALLA PHARMA LTD (ASX), NEP INTERLONG (HKEx), CHARMACY PHAR (HKEx), MEDLAB CLINICAL LIMITED (ASX), WAI YUEN TONG (HKEx), TBG DIAGNOSTICS LTD (ASX), IMMURON LIMITED (ASX), EXTRAWELL PHAR (HKEx), INVION LTD (ASX), JCT (SET), PURAPHARM (HKEx), ACRUX (ASX), TALI DIGITAL LIMITED (ASX), SUNZEN (Bursa), PHARMAXIS (ASX), SINOLIFE UTD (HKEx), FIJI KAVA LTD (ASX), TIMBER PHARMACEUTICALS INC (NYSE American), SUDA PHARMACEUTICALS LTD (ASX), CELLMID LIMITED (ASX), FARMAFORCE LTD (ASX), PASHUN INT'L (HKEx), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days ---
10 Days -+0.560
+22.13 %
20 Days -+0.210
+7.29 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 1.900 - 3.970 Change From 1 Year Low +1.190 % Change From 1 Year Low (%) +62.63
Change From 1 Year High -0.880 % Change From 1 Year High (%) -22.17
2 Years Range 1.900 - 3.970 Change From 2 Years Low +1.190 % Change From 2 Years Low (%) +62.63
Change From 2 Years High -0.880 % Change From 2 Years High (%) -22.17
5 Years Range 1.900 - 3.970 Change From 5 Years Low +1.190 % Change From 5 Years Low (%) +62.63
Change From 5 Years High -0.880 % Change From 5 Years High (%) -22.17
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

180 Life Sciences Corp. develops pharmaceuticals for chronic pain and inflammatory diseases. It operates as a clinical-stage biotechnology company focused on the development of novel drugs that fulfil unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded in 2016 and is headquartered in Menlo Park, CA.

Historical Price Data

Date Open High Low Close Volume VWAP
19 Jan 2021 3.000 3.180 2.840 3.090 1,062,106 -
15 Jan 2021 3.080 3.180 2.950 3.090 1,499,483 -
14 Jan 2021 3.280 3.440 3.050 3.120 1,804,428 -
13 Jan 2021 2.850 3.360 2.670 3.090 3,507,834 -
12 Jan 2021 2.700 3.035 2.565 2.890 2,004,838 -
11 Jan 2021 2.500 2.730 2.460 2.700 1,041,500 -
08 Jan 2021 2.600 2.600 2.510 2.570 315,035 -
07 Jan 2021 2.610 2.630 2.510 2.580 393,001 -
06 Jan 2021 2.710 2.740 2.510 2.530 758,347 -
05 Jan 2021 2.550 2.700 2.450 2.690 904,311 -
04 Jan 2021 2.680 2.700 2.410 2.510 862,359 -
31 Dec 2020 2.720 2.940 2.595 2.730 1,668,416 -
30 Dec 2020 2.750 2.775 2.600 2.660 580,677 -
29 Dec 2020 2.870 2.873 2.660 2.720 488,714 -
28 Dec 2020 2.800 2.880 2.620 2.810 1,047,997 -
24 Dec 2020 2.880 2.900 2.750 2.766 367,786 -
23 Dec 2020 2.790 2.970 2.760 2.880 778,500 -
22 Dec 2020 2.700 2.900 2.630 2.850 1,511,246 -
21 Dec 2020 2.660 2.850 2.600 2.700 1,719,497 -
18 Dec 2020 3.200 3.550 2.720 2.770 17,257,800 -
17 Dec 2020 2.460 3.080 2.380 2.830 3,314,543 -
16 Dec 2020 2.370 2.470 2.280 2.460 692,991 -
Summary
Current 2 Weeks
(05 Jan 2021 to 19 Jan 2021)
2.550 3.440 2.450 3.090 13,290,883 -
Previous 2 Weeks
(18 Dec 2020 to 04 Jan 2021)
3.200 3.550 2.450 2.510 26,282,992 -
4 Weeks from
(19 Nov 2020 to 17 Dec 2020)
2.250 3.440 1.900 2.830 16,595,273 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.